• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重症监护病房革兰氏阳性菌的抗菌药物耐药性

Antimicrobial resistance among gram-positive organisms in the intensive care unit.

作者信息

Clark Nina M, Hershberger Ellie, Zervosc Marcus J, Lynch Joseph P

机构信息

Section of Infectious Diseases, Department of Internal Medicine, University of Illinois at Chicago, Chicago, Illinois, USA.

出版信息

Curr Opin Crit Care. 2003 Oct;9(5):403-12. doi: 10.1097/00075198-200310000-00011.

DOI:10.1097/00075198-200310000-00011
PMID:14508154
Abstract

PURPOSE OF REVIEW

The epidemiology of gram-positive pathogens in the intensive care unit are reviewed, recent trends in antimicrobial resistance among these organisms are discussed, and the significance of these data with respect to treatment are considered.

RECENT FINDINGS

Results of surveillance studies published in 2001 and 2002 have demonstrated that gram-positive organisms such as Staphylococcus aureus, coagulase-negative staphylococci, and enterococci are among the most common bacteria infecting patients in intensive care units. Furthermore, these organisms are becoming increasingly resistant to available antimicrobial agents, and 2002 has ushered in worrisome developments such as the appearance of vancomycin-resistant S. aureus. Community-acquired methicillin-resistant S. aureus and the rise in incidence of vancomycin-resistant enterococci are other problems of great concern. Novel antibiotics such as quinupristin/dalfopristin and linezolid have activity against these agents, but resistance may develop to these agents as well. Studies have shown that infections caused by antibiotic-resistant organisms may be associated with increased morbidity, mortality, and costs. Exposure to antibiotics is a major risk factor for producing antibiotic resistance in patients, and methods to limit the spread of these organisms include restriction of antibiotic use, infection control, surveillance programs, and isolation procedures.

SUMMARY

An awareness of the prevalence and patterns of resistance among gram-positive nosocomial pathogens is vital for the appropriate treatment of hospitalized patients. In addition, efforts must be made to minimize the selection and spread of these organisms.

摘要

综述目的

对重症监护病房中革兰氏阳性病原体的流行病学进行综述,讨论这些微生物中抗菌药物耐药性的近期趋势,并考虑这些数据在治疗方面的意义。

近期发现

2001年和2002年发表的监测研究结果表明,金黄色葡萄球菌、凝固酶阴性葡萄球菌和肠球菌等革兰氏阳性菌是重症监护病房中感染患者最常见的细菌之一。此外,这些微生物对现有抗菌药物的耐药性越来越强,2002年还出现了令人担忧的情况,如万古霉素耐药金黄色葡萄球菌的出现。社区获得性耐甲氧西林金黄色葡萄球菌以及万古霉素耐药肠球菌发病率的上升是其他备受关注的问题。新型抗生素如奎奴普丁/达福普汀和利奈唑胺对这些病原体有活性,但这些药物也可能产生耐药性。研究表明,由耐药菌引起的感染可能与发病率、死亡率和成本增加有关。接触抗生素是患者产生抗生素耐药性的主要危险因素,限制这些微生物传播的方法包括限制抗生素使用、感染控制、监测计划和隔离程序。

总结

了解革兰氏阳性医院病原体的流行情况和耐药模式对于住院患者的恰当治疗至关重要。此外,必须努力尽量减少这些微生物的产生和传播。

相似文献

1
Antimicrobial resistance among gram-positive organisms in the intensive care unit.重症监护病房革兰氏阳性菌的抗菌药物耐药性
Curr Opin Crit Care. 2003 Oct;9(5):403-12. doi: 10.1097/00075198-200310000-00011.
2
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.耐甲氧西林金黄色葡萄球菌和耐万古霉素肠球菌:新出现的问题及管理新前景
Ann Acad Med Singap. 2001 May;30(3):320-31.
3
[Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].利奈唑胺在多重耐药革兰氏阳性病原体所致感染治疗中的前景
Recenti Prog Med. 2007 Mar;98(3):143-54.
4
Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.用于革兰氏阳性菌感染的抗生素。万古霉素、替考拉宁、奎奴普丁/达福普汀和利奈唑胺。
Infect Dis Clin North Am. 2000 Jun;14(2):463-74. doi: 10.1016/s0891-5520(05)70258-0.
5
Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.在外科重症监护病房引入利奈唑胺-万古霉素季度轮换方案后,耐甲氧西林金黄色葡萄球菌感染率降低。
Surg Infect (Larchmt). 2008 Aug;9(4):423-31. doi: 10.1089/sur.2007.024.
6
Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.2004 年至 2009 年期间,在美国进行的替加环素评估和监测试验(TEST)中收集的革兰氏阳性分离株对替加环素和利奈唑胺的敏感性。
Clin Ther. 2011 Dec;33(12):1964-73. doi: 10.1016/j.clinthera.2011.10.010. Epub 2011 Nov 10.
7
Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.奎奴普丁/达福普汀对革兰氏阳性菌的活性:临床应用及治疗潜力。
J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139.
8
Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.耐抗生素革兰氏阳性菌引起的医院感染和社区获得性感染的流行病学趋势:链阳菌素及其他新型化合物的作用
Diagn Microbiol Infect Dis. 1999 Feb;33(2):101-12. doi: 10.1016/s0732-8893(98)00108-4.
9
In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.利奈唑胺与奎奴普丁/达福普汀对革兰氏阳性球菌的体外活性。
Indian J Med Res. 2004 Dec;120(6):546-52.
10
Treatment options for vancomycin-resistant enterococcal infections.耐万古霉素肠球菌感染的治疗选择。
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.

引用本文的文献

1
Genotyping of vancomycin resistant enterococci in arak hospitals.阿拉克医院耐万古霉素肠球菌的基因分型
Jundishapur J Microbiol. 2015 Apr 18;8(4):e16287. doi: 10.5812/jjm.8(4)2015.16287. eCollection 2015 Apr.
2
Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study.危重症外科患者疑似 ICU 获得性感染时采用积极与保守抗菌治疗策略的比较:一项准实验、前后观察性队列研究。
Lancet Infect Dis. 2012 Oct;12(10):774-80. doi: 10.1016/S1473-3099(12)70151-2. Epub 2012 Aug 28.
3
The rising problem of antimicrobial resistance in the intensive care unit.
重症监护病房中抗菌药物耐药性日益严重的问题。
Ann Intensive Care. 2011 Nov 23;1:47. doi: 10.1186/2110-5820-1-47.
4
Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor.通过核输入抑制剂的细胞内肽递送抑制急性肺部炎症
Mol Ther. 2009 May;17(5):796-802. doi: 10.1038/mt.2009.18. Epub 2009 Mar 3.
5
Recent advances in the chemistry and biology of naturally occurring antibiotics.天然抗生素化学与生物学的最新进展。
Angew Chem Int Ed Engl. 2009;48(4):660-719. doi: 10.1002/anie.200801695.
6
Postoperative spinal wound infections and postprocedural diskitis.术后脊柱伤口感染及术后椎间盘炎。
J Spinal Cord Med. 2007;30(5):441-51. doi: 10.1080/10790268.2007.11753476.
7
In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.吡咯并吡唑基取代恶唑烷酮RWJ-416457的体外抗菌活性
Antimicrob Agents Chemother. 2007 Jan;51(1):361-5. doi: 10.1128/AAC.01017-06. Epub 2006 Nov 13.
8
Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.慢性阻塞性肺疾病合并呼吸道感染患者中头孢噻肟持续给药与间歇给药的比较:药代动力学/药效学、细菌敏感性及临床疗效
Br J Clin Pharmacol. 2007 Jan;63(1):100-9. doi: 10.1111/j.1365-2125.2006.02730.x. Epub 2006 Jul 21.
9
Heparan sulfate proteoglycans mediate Staphylococcus aureus interactions with intestinal epithelium.硫酸乙酰肝素蛋白聚糖介导金黄色葡萄球菌与肠上皮细胞的相互作用。
Med Microbiol Immunol. 2006 Sep;195(3):133-41. doi: 10.1007/s00430-005-0007-5. Epub 2005 Dec 24.
10
The N-terminal domain of enterococcal surface protein, Esp, is sufficient for Esp-mediated biofilm enhancement in Enterococcus faecalis.粪肠球菌表面蛋白Esp的N端结构域足以介导粪肠球菌中Esp介导的生物膜增强作用。
J Bacteriol. 2005 Sep;187(17):6213-22. doi: 10.1128/JB.187.17.6213-6222.2005.